当前位置：
X-MOL 学术
›
Health Qual. Life Outcomes
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors.
Health and Quality of Life Outcomes ( IF 3.6 ) Pub Date : 2020-02-10 , DOI: 10.1186/s12955-020-1283-x Winnie Yeo 1, 2 , Elizabeth Pang 1, 2 , Giok S Liem 1 , Joyce J S Suen 1 , Rita Y W Ng 1 , Christopher C H Yip 1 , Leung Li 1 , Claudia H W Yip 1 , Frankie K F Mo 1, 2
Health and Quality of Life Outcomes ( IF 3.6 ) Pub Date : 2020-02-10 , DOI: 10.1186/s12955-020-1283-x Winnie Yeo 1, 2 , Elizabeth Pang 1, 2 , Giok S Liem 1 , Joyce J S Suen 1 , Rita Y W Ng 1 , Christopher C H Yip 1 , Leung Li 1 , Claudia H W Yip 1 , Frankie K F Mo 1, 2
Affiliation
INTRODUCTIONS
For young premenopausal breast cancer patients, adjuvant chemotherapy may cause menstrual disruptions and premature menopause, which may in turn impair their quality of life (QoL). In this study among young breast cancer survivors who have undergone adjuvant chemotherapy, the objectives were to assess post-treatment menopausal symptoms and their associated factors, and to correlate these symptoms with breast cancer-specific QoL.
METHODS
The study population included premenopausal young Chinese women with early-stage breast cancer who had undergone adjuvant chemotherapy between 3 and 10 years prior to enrolling into this study. At study entry, patients' characteristics and clinical features were collected; each patient had detail menstrual history collected and each filled in MENQOL and FACT-B + 4 questionnaires.
RESULTS
Two hundred eighty eligible patients were recruited. For adjuvant chemotherapy, 92% received anthracyclines and 28% received taxanes; 76% received adjuvant tamoxifen. At a median of 5.0 years from initial cancer diagnosis, 49 and 11% had become post- and peri-menopausal respectively. MENQOL at study entry revealed that physical domain score was worse in overweight/obese patients (mean scores for underweight/normal vs overweight/obese: 2.65 vs 2.97, p = 0.0162). Vasomotor domain score was worse in those who received taxanes or tamoxifen (taxane vs non-taxane: 2.91 vs. 2.35, p = 0.0140; tamoxifen vs no tamoxifen: 2.75 vs. 2.34, p = 0.0479). Sexual domain score was worse among those who had become peri/post-menopausal (peri/postmenopausal vs premenopausal: 2.82 vs. 2.29, p = 0.0229). On the other hand, patients who utilized traditional Chinese medicine had significantly worse scores for vasomotor, psychosocial and physical domains. Further, there was a significant association between MENQOL scores and FACT-B + 4 scores; less severe symptoms in the MENQOL domains were associated with better QoL scores in FACT-B + 4 physical, functional, psychosocial and emotional well-being, Breast Cancer Subscale, Arm Subscale and FACT-B total score.
CONCLUSION
Among premenopausal breast cancer women who had undergone adjuvant chemotherapy, those who had received taxanes or tamoxifen, were overweight/obese and utilized traditional Chinese medicine had more severe menopausal symptoms. Patients who experienced worse menopausal symptoms were found to have worse breast cancer-specific QoL. Interventional studies with an aim to alleviate menopausal symptoms are warranted to assess if overall QoL of these patients could be improved.
TRIAL REGISTRATION
Not applicable.
更新日期：2020-02-10
京公网安备 11010802027423号